Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | CPA1 | P15085 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492736 | 0.78 | CYP2D6 (0.35) | LMNAKMT2A | |
| SCHEMBL22205063 | 0.74 | CPA1 (0.52) | ANPEPENPEPCPA1LMNA | |
| SCHEMBL14535008 | 0.73 | CTSK (0.35) | — | |
| SCHEMBL5492741 | 0.73 | CACNA2D1 (0.48) | ANPEPENPEPLMNA | |
| SCHEMBL1410324 | 0.70 | CPA1 (0.56) | CPA1MEN1LMNABLMHBB | |
| SCHEMBL1410060 | 0.70 | CPA1 (0.56) | CPA1MEN1LMNABLMHBB | |
| SCHEMBL1117046 | 0.70 | CPA1 (0.56) | CPA1MEN1LMNABLMHBB | |
| SCHEMBL4342579 | 0.70 | CPA1 (0.39) | CPA1MEN1LMNABLMHBB | |
| Potassium Ion SCHEMBL1410071 | 0.69 | CPA1 (0.55) | CPA1MEN1LMNABLMHBB | |
| SCHEMBL1410050 | 0.69 | CPA1 (0.55) | CPA1MEN1LMNABLMHBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937032-B1 | SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | EP | disclosed |
| US-6153650-A | TREATMENT OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, NEUROPATHOLOGICAL DISORDERS, INFLAMMATION, AND GASTROINTESTINAL DAMAGE. | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0937032-A1 | SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017627-A1 | SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-04-30 | — | — | WO | disclosed |